Which individuals receiving opioid agonist treatment with methadone or buprenorphine are most vulnerable to overdose, and does concurrent substance use increase this risk?

Evidence shows that concurrent substance use, particularly with CNS depressants, significantly elevates overdose risk in individuals on methadone or buprenorphine. Careful monitoring and harm reduction strategies can mitigate these risks.